Lifecore Biomedical, Inc.
LFCR
$4.93
-$0.05-1.00%
NASDAQ
| 03/31/2026 | 09/30/2025 | 05/25/2025 | 05/25/2025 | 02/23/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.43% | 38.44% | 83.81% | 83.81% | -194.48% |
| Total Depreciation and Amortization | 11.27% | -0.60% | -4.97% | -4.97% | 3.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.20% | 49.08% | -39.99% | -39.99% | 214.03% |
| Change in Net Operating Assets | 324.55% | -91.46% | -123.09% | -123.09% | 48.44% |
| Cash from Operations | 291.67% | 374.03% | -38.65% | -38.65% | 184.63% |
| Capital Expenditure | 79.51% | 48.79% | 22.71% | 22.71% | 14.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -172.41% | 48.79% | 22.71% | 22.71% | 124.25% |
| Total Debt Issued | -- | 532.18% | -12.23% | -12.23% | -- |
| Total Debt Repaid | -484.18% | -5,192.70% | 12.55% | 12.55% | -2,585.78% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -96.26% | 77.99% | 77.99% | -216.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 41.15% | -- | -858.76% | -858.76% | -108.92% |
| Cash from Financing | 96.23% | -226.99% | 34.53% | 34.53% | -188.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 182.37% | 53.67% | -47.15% | -47.15% | -2,628.38% |